Kong T.-D.,Third Peoples Hospital of Zhengzhou |
Zhu M.,Third Peoples Hospital of Zhengzhou |
Gao W.-Y.,Third Peoples Hospital of Zhengzhou |
Yao L.-G.,Third Peoples Hospital of Zhengzhou |
And 2 more authors.
Chinese Journal of Cancer Prevention and Treatment | Year: 2014
OBJECTIVE: To observe the effect on quality of life (QOL) in patients treated with S-1 plus oxiliplatin and FOLFOX4.METHODS: Sixty patients were ramdomly divided into SOX group and FOLFOX4 group, SOX group was given S-1 plus oxalipitin, oxaliplatin was administered intravenously on d1 with 130 mg/m2, S-1 was administered orally from d1 to d14 at the following doses on the basis of body surface area (BSA): BSA<1.25 m2, 80 mg daily; 1.25 m2≤BSA<1.5 m2, 100 mg daily; 1.5 m2≤BSA<1.8 m2, 120 mg, daily; BSA>1.8 m2, 140 mg, daily; every 3 weeks as a cycle. Efficacy was evaluated at least after 2 cycles. In FOLFOX4 group oxaliplatin was administered intravenously on d1 with 80 mg/m2, leucovorin was given intravenously on d1 and d2 with 200 mg/m2, 5-FU was intravenous injection on d1 and d2 with 400 mg/m2, and was administered intravenously 22 hours on d1 and d2 with 600 mg/m2. The assessment methods of QOF was QLQ-CR68 questionnaire.RESULTS: Patients' background and characteristics were similar, all of the 60 patients could be evaluated. The overall response rate in SOX was 46.7% and in FOLFOX4 it was 36.7%, χ2=0.617, P=0.432. In questionnaire questions such as fatigue, nausea and vomiting, gastrointestinal symptoms, pain, appetite loss, urination, defecation and weight loss were inquired, comparing the improvement of life quality between the two groups, SOX was improved more obviously in relieving of nausea and vomiting, chemotherapy toxicity, gastrointestinal symptoms, defecation, and weight loss, the P values were all less than 0.05.In total heath score, SOX(70.03±16.15) and FOLFOX4(60.46±15.31) groups showed significantly better results than before chemotherapy. Furthermore, the SOX team was improved deeply before and after chemotherapy between the two groups, t=2.076 9, P=0.0423.CONCLUSIONS: The present results suggest that questionnaires are useful for assessing patients' QOL with advanced CRC treated chemotherapy. Combination chemotherapy with oral fluoropyrimidine S-1 plus oxiliplatin could improve QOL better than Folfox4, we can increase the sample size in the further research.
Han L.-J.,Third Peoples Hospital of Zhengzhou |
Ma H.-X.,Third Peoples Hospital of Zhengzhou |
Dong X.-J.,Third Peoples Hospital of Zhengzhou |
Wang X.-J.,Third Peoples Hospital of Zhengzhou |
And 3 more authors.
Journal of Leukemia and Lymphoma | Year: 2012
Objective: To analyse the etiology, clinical characteristics and risk factors of central nervous system (CNS) complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: The clinical features of CNS complications in patients who underwent allo-HSCT were observed, and analysis its causes and risk factors. Results: 8 cases of CNS complications occured in 69 patients within 6 months after allo-HSCT and the incidence was 11.6 %, the occurrence rate of CNS complications was 21.4 % (6/28) in HLA mismatched group, higher than HLA matched group [4.9 % (2/41)] (P < 0.05). Analogously, the incidence was 44.4 % (4/60) in patients with graft-versus-host disease (GVHD) (>grade 2), which was significantly higher than patients with 2 or below grade 2 GVHD [6.7 % (4/9)] (P < 0.01). But there was no significant difference in the incidence of CNS complications between ≤ 14 years old and >14 years old, with or without ATG, different stages of diseases, whether pretreatment with maryland respectively (P > 0.05), either. Epilepsy and intracranial infection were the most common CNS complications in allo-HSCT, followed by intracranial hemorrhage. Conclusion: HLA mismatched and above grade 2 GVHD are the risk factors of CNS complications in allo-HSCT. Epilepsy,intracranial infection and bleeding are common CNS complications in allo-HSCT.